Roche/Memory Alzheimer’s Trial Will Proceed Following Lift Of Clinical Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Memory will launch a Phase IIa trial of MEM 3454 in first quarter 2007 after it resolved FDA questions about toxicology reports.
You may also be interested in...
Memory Alzheimer’s Disease Candidate Shows Cognitive Benefit In Phase II
Firm expects Roche to make a decision on an option for the nicotinic alpha-7 receptor partial agonist in the first half of 2008.
Memory Alzheimer’s Disease Candidate Shows Cognitive Benefit In Phase II
Firm expects Roche to make a decision on an option for the nicotinic alpha-7 receptor partial agonist in the first half of 2008.
Memory, Roche Rewrite Deal To Support Phase IIa Trial In Schizophrenia Cognitive Impairment Treatment
Roche agrees to extra milestone payment for nicotinic alpha-7 agonist MEM 3454, but relinquishes rights to PDE4 inhibitor program.